Nintedanib (BIBF 1120) is a potent, oral, small-molecule tyrosine kinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β signaling [6], and has been recently approved for second line treatment of non-small cell lung cancer (NSCLC) of adenocarcinoma histology in combination with docetaxel. This evidence concerns the gene FLT1 and non-small cell lung carcinoma.